Akers Biosciences and Premas Biotech Reports Successful Expression of Three Coronavirus Antigens | Financial Buzz

Akers Biosciences and Premas Biotech Reports Successful Expression of Three Coronavirus Antigens

Akers Biosciences, Inc. (NASDAQ: AKER) announced Wednesday that its collaboration with Premas Biotech has successfully completed a second milestone, the effective expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate.

Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas’ key focus areas are infectious diseases, cancer, metabolic disorders and inflammation.

The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which we believe should lead to a scaling up of the antigens.

Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented, “We are happy to announce our success in expressing all three antigens. We continue to believe that the immune system is better served with three shots on goal and our inclusion of the S, E, and M antigens together should enhance the efficacy of our vaccine candidate. We are also pleased with the expedited nature of our milestones thus far, which is a positive step towards our goal to reach clinical trials.”

Christopher Schreiber, Executive Chairman of Akers, stated, “We are now halfway through our four-milestone plan that we believe will allow us to commence clinical trials. Our partnership with Premas is executing very well and we look forward to sharing the next milestones as they occur in the weeks to come.”